US5587308A
(en)
*
|
1992-06-02 |
1996-12-24 |
The United States Of America As Represented By The Department Of Health & Human Services |
Modified adeno-associated virus vector capable of expression from a novel promoter
|
US5869305A
(en)
*
|
1992-12-04 |
1999-02-09 |
The University Of Pittsburgh |
Recombinant viral vector system
|
US6686200B1
(en)
*
|
1993-08-31 |
2004-02-03 |
Uab Research Foundation |
Methods and compositions for the large scale production of recombinant adeno-associated virus
|
US6652850B1
(en)
*
|
1993-09-13 |
2003-11-25 |
Aventis Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
US5834441A
(en)
*
|
1993-09-13 |
1998-11-10 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral (AAV) liposomes and methods related thereto
|
FR2716459B1
(fr)
*
|
1994-02-22 |
1996-05-10 |
Univ Paris Curie |
Système hôte-vecteur utilisable en thérapie génique.
|
FR2716893B1
(fr)
*
|
1994-03-03 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, leur préparation et leur utilisation thérapeutique.
|
EP0755454B1
(en)
*
|
1994-04-13 |
2008-02-13 |
The Rockefeller University |
Aav-mediated delivery of dna to cells of the nervous system
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
US5658785A
(en)
*
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
US5856152A
(en)
*
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
US6342390B1
(en)
|
1994-11-23 |
2002-01-29 |
The United States Of America As Represented By The Secretary Of Health And Human Services |
Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
|
US6924128B2
(en)
*
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
US6383814B1
(en)
*
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
US6187757B1
(en)
|
1995-06-07 |
2001-02-13 |
Ariad Pharmaceuticals, Inc. |
Regulation of biological events using novel compounds
|
US5646034A
(en)
*
|
1995-06-07 |
1997-07-08 |
Mamounas; Michael |
Increasing rAAV titer
|
US6110456A
(en)
*
|
1995-06-07 |
2000-08-29 |
Yale University |
Oral delivery or adeno-associated viral vectors
|
AU6504596A
(en)
*
|
1995-07-21 |
1997-02-18 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
US6207457B1
(en)
*
|
1995-09-08 |
2001-03-27 |
Avigen, Inc. |
Targeted nucleotide sequence delivery and integration system
|
US6086913A
(en)
*
|
1995-11-01 |
2000-07-11 |
University Of British Columbia |
Liposomal delivery of AAV vectors
|
CA2279675A1
(en)
*
|
1995-12-15 |
1997-06-16 |
Enzo Therapeutics, Inc. |
Property effecting and/or property exhibiting constructs for localizing a nucleic acid construct within a cell for therapeutic and diagnostic uses
|
US5858351A
(en)
*
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
DE19608753C1
(de)
*
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
US6245735B1
(en)
|
1996-07-29 |
2001-06-12 |
The Brigham And Women's Hospital, Inc. |
Methods and products for treating pseudomonas infection
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
AU4645697A
(en)
|
1996-09-11 |
1998-04-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Aav4 vector and uses thereof
|
DE69840439D1
(de)
|
1997-04-24 |
2009-02-26 |
Univ Washington |
Zielgerichtete genveraenderung mit parvoviralen vektoren
|
US6156303A
(en)
*
|
1997-06-11 |
2000-12-05 |
University Of Washington |
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6995006B2
(en)
*
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6642051B1
(en)
|
1997-10-21 |
2003-11-04 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
|
US6346415B1
(en)
*
|
1997-10-21 |
2002-02-12 |
Targeted Genetics Corporation |
Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
|
JP2001520047A
(ja)
*
|
1997-10-21 |
2001-10-30 |
ターゲテッド ジェネティックス コーポレイション |
組換えaavベクターと共に使用するための転写活性化された逆方向末端反復(itr)
|
AU759573B2
(en)
|
1997-12-23 |
2003-04-17 |
Crucell Holland B.V. |
Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal DNA of target cells
|
US6984635B1
(en)
|
1998-02-13 |
2006-01-10 |
Board Of Trustees Of The Leland Stanford Jr. University |
Dimerizing agents, their production and use
|
US6294379B1
(en)
*
|
1998-02-25 |
2001-09-25 |
The Regents Of The University Of California |
Efficient AAV vectors
|
JP2002509716A
(ja)
|
1998-03-31 |
2002-04-02 |
ユニバーシティ テクノロジー コーポレイション |
テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物
|
CA2326327C
(en)
*
|
1998-04-24 |
2009-06-16 |
University Of Florida |
Recombinant adeno-associated virus vector encoding alpha-1-antitrypsin serum protein
|
DE69928244T2
(de)
|
1998-05-06 |
2006-08-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
Inhibitoren der nf-kb aktivierung
|
EP1080218A1
(en)
|
1998-05-27 |
2001-03-07 |
University of Florida |
Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
|
US6984517B1
(en)
|
1998-05-28 |
2006-01-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector and uses thereof
|
CA2745131C
(en)
|
1998-05-28 |
2016-08-09 |
John A. Chiorini |
Aav5 vector and uses thereof
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
US6200560B1
(en)
*
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
US6395549B1
(en)
|
1998-10-22 |
2002-05-28 |
Medical College Of Georgia Research Institute, Inc. |
Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
|
US7129043B1
(en)
*
|
1998-10-22 |
2006-10-31 |
Duke University |
Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
|
US6468793B1
(en)
|
1998-10-23 |
2002-10-22 |
Florida State University Research Foundation |
CFTR genes and proteins for cystic fibrosis gene therapy
|
US6759237B1
(en)
*
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
US6491907B1
(en)
|
1998-11-10 |
2002-12-10 |
The University Of North Carolina At Chapel Hill |
Recombinant parvovirus vectors and method of making
|
US6387368B1
(en)
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
US6893865B1
(en)
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
US6537540B1
(en)
|
1999-05-28 |
2003-03-25 |
Targeted Genetics Corporation |
Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
|
CN1379819A
(zh)
|
1999-06-28 |
2002-11-13 |
俄克拉荷马州医学研究基金会 |
具有催化活性的重组memapsin蛋白酶及其应用方法
|
ES2308989T3
(es)
*
|
1999-08-09 |
2008-12-16 |
Targeted Genetics Corporation |
Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
|
AU7879000A
(en)
*
|
1999-10-12 |
2001-04-23 |
University Of North Carolina At Chapel Hill, The |
Adeno-associated virus vectors encoding factor viii and methods of using the same
|
WO2001059450A2
(en)
|
2000-02-08 |
2001-08-16 |
Sangamo Biosciences, Inc. |
Cells expressing zinc finger protein for drug discovery
|
WO2001066782A1
(en)
*
|
2000-03-03 |
2001-09-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral compositions and methods
|
US6855314B1
(en)
|
2000-03-22 |
2005-02-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
AAV5 vector for transducing brain cells and lung cells
|
AU2001250922A1
(en)
*
|
2000-03-22 |
2001-10-03 |
Board Of Trustees Of The University Of Arkansas |
Secreting products from skin by adeno-associated virus (aav) gene transfer
|
AU2002342653A1
(en)
|
2001-05-14 |
2002-11-25 |
The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health |
Modified growth hormone
|
AU2002303832A1
(en)
|
2001-05-21 |
2002-12-03 |
Beth Israel Deaconess Medical Center, Inc. |
P.aeruginosa mucoid exopolysaccharide specific binding peptides
|
US7119172B2
(en)
|
2001-05-21 |
2006-10-10 |
The Brigham And Women's Hospital, Inc. |
P. aeruginosa mucoid exopolysaccharide specific binding peptides
|
US8216585B2
(en)
*
|
2001-05-25 |
2012-07-10 |
The Trustees Of The University Of Pennsylvania |
Targeted particles and methods of using the same
|
CA2447249A1
(en)
|
2001-06-22 |
2003-01-03 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Abin-mediated hepatitis protection
|
EP1435779A4
(en)
|
2001-09-24 |
2005-06-01 |
Sangamo Biosciences Inc |
MODULATION OF STEM CELLS USING ZINC FINGER PROTEINS (ZFP)
|
EP1474444A1
(en)
|
2002-01-10 |
2004-11-10 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
A novel splice variant of myd88 and uses thereof
|
AU2003225791A1
(en)
|
2002-03-15 |
2003-09-29 |
Department Of Veterans Affairs, Rehabilitation R And D Service |
Methods and compositions for directing cells to target organs
|
US6825263B2
(en)
*
|
2002-04-08 |
2004-11-30 |
Dow Corning Corporation |
Curable coating compositions from emulsions of elastomeric polymers and polyurethane dispersions
|
MXPA04010282A
(es)
|
2002-04-18 |
2005-08-18 |
Acuity Pharmaceuticals Inc |
Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
EP1562970A4
(en)
|
2002-11-01 |
2006-04-12 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR INHIBITING HIF-1 ALPHA WITH ARNS
|
WO2004043387A2
(en)
|
2002-11-13 |
2004-05-27 |
Thomas Jefferson University |
Compositions and methods for cancer diagnosis and therapy
|
AU2003300076C1
(en)
|
2002-12-30 |
2010-03-04 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
EP2251434B1
(en)
|
2003-01-16 |
2014-07-30 |
The Trustees of The University of Pennsylvania |
Compositions and methods for siRNA inhibition of ICAM-1
|
US8927269B2
(en)
|
2003-05-19 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Avian adenoassociated virus and uses thereof
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
EP3222715A1
(en)
|
2003-08-08 |
2017-09-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
CA2539439C
(en)
|
2003-09-19 |
2012-10-23 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
WO2005056807A2
(en)
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
EP2295604B1
(en)
|
2004-02-09 |
2015-04-08 |
Thomas Jefferson University |
Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
AU2005222963B2
(en)
*
|
2004-03-15 |
2009-10-29 |
Biogen Idec Ma Inc. |
Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
|
CA2561565C
(en)
|
2004-04-08 |
2013-11-26 |
Sangamo Biosciences, Inc. |
Methods for repression of phospholamban gene and modulating cardiac contractility
|
US20080131962A1
(en)
|
2006-05-25 |
2008-06-05 |
Sangamo Biosciences, Inc. |
Engineered cleavage half-domains
|
WO2006036465A2
(en)
*
|
2004-09-03 |
2006-04-06 |
University Of Florida |
Compositions and methods for treating cystic fibrosis
|
CA2579677A1
(en)
|
2004-09-16 |
2006-03-30 |
Sangamo Biosciences, Inc. |
Compositions and methods for protein production
|
NZ555830A
(en)
*
|
2004-12-15 |
2009-01-31 |
Univ North Carolina |
Chimeric vectors
|
US7358085B2
(en)
|
2005-02-28 |
2008-04-15 |
Sangamo Biosciences, Inc. |
Anti-angiogenic methods and compositions
|
WO2006111404A2
(de)
|
2005-04-22 |
2006-10-26 |
Evonik Stockhausen Gmbh |
Oberflächennachvernetzte superabsorber behandelt mit metallsalz und metalloxid
|
WO2006119432A2
(en)
|
2005-04-29 |
2006-11-09 |
The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services |
Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
|
WO2007014275A2
(en)
|
2005-07-26 |
2007-02-01 |
Sangamo Biosciences, Inc. |
Targeted integration and expression of exogenous nucleic acid sequences
|
EP1937280B1
(en)
|
2005-09-12 |
2014-08-27 |
The Ohio State University Research Foundation |
Compositions for the therapy of bcl2-associated cancers
|
EP2345417A1
(en)
|
2005-12-22 |
2011-07-20 |
Vib Vzw |
Means and methods for mediating protein interference
|
US8669418B2
(en)
|
2005-12-22 |
2014-03-11 |
Vib Vzw |
Means and methods for mediating protein interference
|
MX2008008302A
(es)
|
2005-12-22 |
2009-01-21 |
Exegenics Inc |
Composiciones y metodos para regular el sistema de complemento.
|
AU2007205257B2
(en)
|
2006-01-05 |
2013-07-25 |
The Ohio State University Research Foundation |
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
|
EP2468899B1
(en)
|
2006-01-05 |
2015-03-11 |
The Ohio State University Research Foundation |
MicroRNA-based methods for the diagnosis of stomach cancers
|
CN102943108B
(zh)
|
2006-01-05 |
2014-05-21 |
俄亥俄州立大学研究基金会 |
用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
|
EP2522747A1
(en)
|
2006-03-02 |
2012-11-14 |
The Ohio State University |
MicroRNA expression profile associated with pancreatic cancer
|
AU2007227423B2
(en)
|
2006-03-20 |
2013-11-07 |
The Ohio State University Research Foundation |
MicroRNA fingerprints during human megakaryocytopoiesis
|
US7718629B2
(en)
|
2006-03-31 |
2010-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 gene
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
JP5570806B2
(ja)
|
2006-05-11 |
2014-08-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Pcsk9遺伝子の発現を阻害するための組成物および方法
|
US7812150B2
(en)
|
2006-05-19 |
2010-10-12 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
ES2390499T3
(es)
|
2006-06-12 |
2012-11-13 |
Opko Pharmaceuticals, Llc |
Composiciones y métodos para la inhibición de la angiogénesis por sirna
|
EP2369017B8
(en)
|
2006-07-13 |
2014-03-12 |
The Ohio State University Research Foundation |
Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
|
PL2044199T3
(pl)
*
|
2006-07-25 |
2013-04-30 |
Celladon Corp |
Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
|
US7872118B2
(en)
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
AU2007299629C1
(en)
|
2006-09-21 |
2012-05-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the HAMP gene
|
WO2008115387A2
(en)
|
2007-03-15 |
2008-09-25 |
University Hospitals Of Cleveland |
Screening, diagnosing, treating and prognosis of pathophysiologic states by rna regulation
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
EP2136832B1
(en)
|
2007-03-26 |
2015-09-02 |
General Regeneratives Limited |
Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
|
US7759320B2
(en)
|
2007-03-29 |
2010-07-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the Ebola
|
EP2319926B1
(en)
|
2007-07-05 |
2016-08-31 |
Arrowhead Research Corporation |
DSRNA for treating viral infection
|
US7919313B2
(en)
|
2007-07-12 |
2011-04-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
|
WO2009012263A2
(en)
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
WO2009018303A2
(en)
|
2007-07-31 |
2009-02-05 |
The Ohio State University Research Foundation |
Methods for reverting methylation by targeting dnmt3a and dnmt3b
|
CN103866008B
(zh)
|
2007-08-03 |
2016-06-29 |
俄亥俄州立大学研究基金会 |
编码ncrna的超保守区域
|
CA2696887C
(en)
|
2007-08-22 |
2016-06-28 |
The Ohio State University Research Foundation |
Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
|
EP2775001B1
(en)
|
2007-09-06 |
2016-03-09 |
The Ohio State University Research Foundation |
MicroRNA signatures in human ovarian cancer
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
US20100285471A1
(en)
|
2007-10-11 |
2010-11-11 |
The Ohio State University Research Foundation |
Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas
|
EP2612868B1
(en)
|
2007-11-01 |
2018-08-15 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
EP2848688A1
(en)
|
2007-12-10 |
2015-03-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US8221738B2
(en)
|
2008-02-19 |
2012-07-17 |
Celladon Corporation |
Method for enhanced uptake of viral vectors in the myocardium
|
CN105267233B
(zh)
|
2008-03-05 |
2019-07-26 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
CA2893175C
(en)
|
2008-06-10 |
2016-09-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for generation of bax- and bak-deficient cell lines
|
KR101759586B1
(ko)
|
2008-08-22 |
2017-07-19 |
상가모 테라퓨틱스, 인코포레이티드 |
표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물
|
EP2690175B1
(en)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression
|
JP5529142B2
(ja)
|
2008-09-25 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法
|
EA020312B1
(ru)
|
2008-10-20 |
2014-10-30 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
BRPI0922122A2
(pt)
|
2008-11-30 |
2017-08-01 |
Immusant Inc |
composições e métodos para tratamento de doença celíaca.
|
EP2361306A1
(en)
|
2008-12-04 |
2011-08-31 |
OPKO Ophthalmics, LLC |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
US8551945B2
(en)
|
2009-02-04 |
2013-10-08 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating neuropathies
|
EP2396343B1
(en)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modified virus vectors and methods of making and using the same
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
EP2406376A1
(en)
|
2009-03-12 |
2012-01-18 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
KR101764437B1
(ko)
|
2009-03-20 |
2017-08-02 |
메소블라스트, 아이엔씨. |
재프로그램된 다분화능 세포의 생성 방법
|
WO2010117464A1
(en)
|
2009-04-09 |
2010-10-14 |
Sangamo Biosciences, Inc. |
Targeted integration into stem cells
|
JP5879256B2
(ja)
|
2009-05-02 |
2016-03-08 |
ジェンザイム・コーポレーション |
神経変性障害のための遺伝子治療
|
WO2011005799A2
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
DK3178490T3
(da)
|
2009-07-15 |
2022-06-20 |
Glaxosmithkline Biologicals Sa |
RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse
|
US9234016B2
(en)
|
2009-07-28 |
2016-01-12 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for treating trinucleotide repeat disorders
|
EP2810643A3
(en)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
|
JP2013509422A
(ja)
|
2009-10-30 |
2013-03-14 |
シーエヌエス セラピューティクス,インク. |
改良されたニュールツリン分子
|
CN105031618A
(zh)
|
2009-11-02 |
2015-11-11 |
加利福尼亚大学董事会 |
用于细胞因子递送的穹窿体复合物
|
US8551781B2
(en)
|
2009-11-19 |
2013-10-08 |
The Regents Of The University Of California |
Vault complexes for facilitating biomolecule delivery
|
CA2782728A1
(en)
|
2009-12-04 |
2011-06-09 |
Opko Ophthalmics, Llc |
Compositions and methods for inhibition of vegf
|
JP6137596B2
(ja)
|
2010-02-08 |
2017-05-31 |
サンガモ セラピューティクス, インコーポレイテッド |
遺伝子操作された切断ハーフドメイン
|
EP2660318A1
(en)
|
2010-02-09 |
2013-11-06 |
Sangamo BioSciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
WO2011123468A1
(en)
|
2010-03-29 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
EP4385568A2
(en)
|
2010-04-06 |
2024-06-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
AU2011256838B2
(en)
|
2010-05-17 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Novel DNA-binding proteins and uses thereof
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
AU2011274510A1
(en)
|
2010-07-09 |
2013-01-24 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
US9057057B2
(en)
|
2010-07-27 |
2015-06-16 |
The Johns Hopkins University |
Obligate heterodimer variants of foki cleavage domain
|
EP3118316A1
(en)
|
2010-09-02 |
2017-01-18 |
Université de Mons |
Agents useful in treating facioscapulohumeral muscular dystrophy
|
CA2811364C
(en)
|
2010-09-27 |
2022-01-04 |
Sangamo Biosciences, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
ES2716243T3
(es)
|
2010-10-11 |
2019-06-11 |
Glaxosmithkline Biologicals Sa |
Plataformas de suministro de antígenos
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
EP2648763A4
(en)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
|
EP3527224A1
(en)
|
2011-01-26 |
2019-08-21 |
GlaxoSmithKline Biologicals S.A. |
Rsv immunization regimen
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
KR102481317B1
(ko)
|
2011-03-29 |
2022-12-26 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
PT2707385T
(pt)
|
2011-05-13 |
2017-12-19 |
Glaxosmithkline Biologicals Sa |
Antigénios de f de rsv pré-fusão
|
EP2714906A1
(en)
|
2011-06-01 |
2014-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for adjusting expression of mitochondrial genome by microrna
|
ES2923573T3
(es)
|
2011-06-21 |
2022-09-28 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
|
US20140275211A1
(en)
|
2011-06-21 |
2014-09-18 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
US9315813B2
(en)
|
2011-06-21 |
2016-04-19 |
Alnylam Pharmaceuticals, Inc |
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
EP3461896B1
(en)
|
2011-07-15 |
2023-11-29 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
EP3613852A3
(en)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
EP2739735A2
(en)
|
2011-08-01 |
2014-06-11 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
EP3498833B1
(en)
|
2011-09-21 |
2023-08-16 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of transgene expression
|
EP2768530A1
(en)
|
2011-10-11 |
2014-08-27 |
Novartis AG |
Recombinant self-replicating polycistronic rna molecules
|
WO2013054199A2
(en)
|
2011-10-12 |
2013-04-18 |
Novartis Ag |
Cmv antigens and uses thereof
|
AU2012323924A1
(en)
|
2011-10-14 |
2014-05-29 |
The Ohio State University |
Methods and materials related to ovarian cancer
|
US20140288156A1
(en)
|
2011-10-27 |
2014-09-25 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods for the treatment and diagnosis of atherosclerosis
|
US9375491B2
(en)
|
2011-10-28 |
2016-06-28 |
University Of Florida Research Foundation, Inc. |
Chimeric promoter for cone photoreceptor targeted gene therapy
|
KR20140123571A
(ko)
|
2012-02-16 |
2014-10-22 |
에이티와이알 파마, 인코포레이티드 |
자가면역 및 염증성 질환의 치료를 위한 히스티딜trna 신테타제
|
CN108285491B
(zh)
|
2012-02-29 |
2021-08-10 |
桑格摩生物科学股份有限公司 |
治疗亨廷顿氏病的方法和组合物
|
US20150190532A1
(en)
|
2012-04-04 |
2015-07-09 |
The Trustees Of Columbia University In The City Of New York |
Smooth muscle specific inhibition for anti-restenotic therapy
|
WO2013153082A1
(en)
|
2012-04-10 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of nonalcoholic steatohepatitis
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
WO2013153139A1
(en)
|
2012-04-11 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and diagnosis of acute leukemia
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
WO2014011705A1
(en)
|
2012-07-09 |
2014-01-16 |
The Regents Of The University Of California |
Vault immunotherapy
|
HUE030799T2
(en)
|
2012-07-11 |
2017-06-28 |
Sangamo Biosciences Inc |
Methods and preparations for the treatment of lysosomal storage diseases
|
EP2872154B1
(en)
|
2012-07-11 |
2017-05-31 |
Sangamo BioSciences, Inc. |
Methods and compositions for delivery of biologics
|
AU2013308770B2
(en)
|
2012-08-29 |
2019-01-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
EP2906684B8
(en)
|
2012-10-10 |
2020-09-02 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
EP2906602B1
(en)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
HUE035887T2
(en)
|
2012-12-05 |
2018-05-28 |
Alnylam Pharmaceuticals Inc |
PCSK9 iRNA preparations and methods for their use
|
EP2928303A4
(en)
|
2012-12-07 |
2016-07-13 |
Haplomics Inc |
FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
EP3825401A1
(en)
|
2012-12-12 |
2021-05-26 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
US20140186843A1
(en)
|
2012-12-12 |
2014-07-03 |
Massachusetts Institute Of Technology |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
MX2015007550A
(es)
|
2012-12-12 |
2017-02-02 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
EP4279588A3
(en)
|
2012-12-12 |
2024-01-17 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
SG10201912327SA
(en)
|
2012-12-12 |
2020-02-27 |
Broad Inst Inc |
Engineering and Optimization of Improved Systems, Methods and Enzyme Compositions for Sequence Manipulation
|
JP6445462B2
(ja)
|
2013-02-07 |
2018-12-26 |
ザ ジェネラル ホスピタル コーポレイション |
Tale転写活性化因子
|
EP3699592A1
(en)
|
2013-03-13 |
2020-08-26 |
Geneweave Biosciences Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
SI2970974T1
(sl)
|
2013-03-14 |
2017-12-29 |
Alnylam Pharmaceuticals, Inc. |
Komplementarna komponenta C5 sestavkov IRNA in postopki njene uporabe
|
EP2978446B1
(en)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antibody for use in treating alzheimer's disease
|
CN116083487A
(zh)
|
2013-05-15 |
2023-05-09 |
桑格摩生物治疗股份有限公司 |
用于治疗遗传病状的方法和组合物
|
CN113018307A
(zh)
|
2013-05-22 |
2021-06-25 |
阿尔尼拉姆医药品有限公司 |
SERPINA1 iRNA组合物及其使用方法
|
IL293657A
(en)
|
2013-05-22 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Preparations of tmprss6 irna and methods of using them
|
EP3071598B1
(en)
|
2013-05-29 |
2021-07-07 |
Vybion, Inc. |
Single chain intrabodies that alter huntingtin mutant degradation
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
CN105492611A
(zh)
|
2013-06-17 |
2016-04-13 |
布罗德研究所有限公司 |
用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
AU2014281026B2
(en)
|
2013-06-17 |
2020-05-28 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
WO2014204728A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
EP3011034B1
(en)
|
2013-06-17 |
2019-08-07 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
CA2920899C
(en)
|
2013-08-28 |
2023-02-28 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
EP3052626A1
(en)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
PL3052628T3
(pl)
|
2013-10-04 |
2020-08-24 |
Alnylam Pharmaceuticals, Inc. |
Kompozycje i sposoby hamowania ekspresji genu ALAS1
|
CN105899665B
(zh)
|
2013-10-17 |
2019-10-22 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
CA2929179A1
(en)
|
2013-11-11 |
2015-05-14 |
Sangamo Biosciences, Inc. |
Htt genetic repressor, viral vector, and uses thereof
|
DK3068881T3
(da)
|
2013-11-13 |
2019-04-15 |
Childrens Medical Center |
Nuklease-medieret regulering af genekspression
|
US9771403B2
(en)
|
2013-12-09 |
2017-09-26 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating hemophilia
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
WO2015089368A2
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
WO2015086828A1
(en)
|
2013-12-12 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
|
MX2016007328A
(es)
|
2013-12-12 |
2017-07-19 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma.
|
CN106536729A
(zh)
|
2013-12-12 |
2017-03-22 |
布罗德研究所有限公司 |
使用粒子递送组分靶向障碍和疾病的crispr‑cas系统和组合物的递送、用途和治疗应用
|
KR20160089530A
(ko)
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Hbv 및 바이러스 질병 및 질환을 위한 crisprcas 시스템 및 조성물의 전달,용도 및 치료적 적용
|
US10072066B2
(en)
|
2014-02-03 |
2018-09-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
JP6594902B2
(ja)
|
2014-02-11 |
2019-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物及びその使用方法
|
US9624498B2
(en)
|
2014-03-18 |
2017-04-18 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
US11110154B2
(en)
|
2014-05-08 |
2021-09-07 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating Huntington's Disease
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
MX2016015126A
(es)
|
2014-05-22 |
2017-02-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP3674408A1
(en)
|
2014-06-16 |
2020-07-01 |
The Johns Hopkins University |
Compositions and methods for the expression of crispr guide rnas
|
KR102330593B1
(ko)
|
2014-07-28 |
2021-11-26 |
에스케이이노베이션 주식회사 |
신규 이소프렌 신타아제 및 이를 이용한 이소프렌의 제조방법
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
WO2016028682A1
(en)
|
2014-08-17 |
2016-02-25 |
The Broad Institute Inc. |
Genome editing using cas9 nickases
|
EP3186368B1
(en)
|
2014-08-25 |
2020-01-15 |
Geneweave Biosciences Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
CA2957800A1
(en)
|
2014-09-07 |
2016-03-10 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector immune responses
|
EP3878948A1
(en)
|
2014-09-16 |
2021-09-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
RU2020109343A
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
MX2017006216A
(es)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
|
DK3218386T3
(da)
|
2014-11-14 |
2021-06-07 |
Voyager Therapeutics Inc |
Modulatorisk polynukleotid
|
EP3221451A1
(en)
|
2014-11-17 |
2017-09-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
EP3230452A1
(en)
|
2014-12-12 |
2017-10-18 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
EP3256587A2
(en)
|
2015-02-13 |
2017-12-20 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
LT3277814T
(lt)
*
|
2015-04-03 |
2020-10-26 |
University Of Massachusetts |
Oligonukleotidų junginiai, skirti nukreipimui į hantingtino mrnr
|
ES2959608T3
(es)
|
2015-04-03 |
2024-02-27 |
Dana Farber Cancer Inst Inc |
Composición y métodos de edición del genoma de células B
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
EP3666895A1
(en)
|
2015-06-18 |
2020-06-17 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
EP3322297A4
(en)
|
2015-07-13 |
2019-04-17 |
Sangamo Therapeutics, Inc. |
RELEASE METHOD AND COMPOSITIONS FOR NUCLEASE-DERIVED GENOMINE ENGINEERING
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
EP3365441A1
(en)
|
2015-10-22 |
2018-08-29 |
The Broad Institute Inc. |
Type vi-b crispr enzymes and systems
|
IL294014B1
(en)
|
2015-10-23 |
2024-03-01 |
Harvard College |
Nucleobase editors and their uses
|
CA3006569A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
US20190233814A1
(en)
|
2015-12-18 |
2019-08-01 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
EA201891212A1
(ru)
|
2015-12-18 |
2019-01-31 |
Сангамо Терапьютикс, Инк. |
Адресная дезорганизация клеточного рецептора гкгс
|
CA3008413A1
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
US11040114B2
(en)
|
2015-12-24 |
2021-06-22 |
Oxyrane Uk Limited |
Human alpha-N-acetylgalactosaminidase polypeptide
|
SG11201805680SA
(en)
|
2016-01-15 |
2018-07-30 |
Sangamo Therapeutics Inc |
Methods and compositions for the treatment of neurologic disease
|
AU2017210726B2
(en)
|
2016-01-31 |
2023-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
EP3411056A4
(en)
|
2016-02-02 |
2019-10-02 |
Sangamo Therapeutics, Inc. |
COMPOUNDS FOR NETWORKING DNA BINDING DOMAINS AND SPLITTING DOMAINS
|
EP3416726A4
(en)
|
2016-02-17 |
2019-08-28 |
Children's Medical Center Corporation |
FFA1 (GPR40) as a therapeutic target for neural diseases or disorders related to angiogenesis
|
WO2017189308A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
KR102670601B1
(ko)
|
2016-04-19 |
2024-05-29 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
US11286478B2
(en)
|
2016-04-19 |
2022-03-29 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
CN109831916B
(zh)
|
2016-05-18 |
2023-07-21 |
沃雅戈治疗公司 |
治疗亨廷顿氏舞蹈病的组合物和方法
|
IL302748A
(en)
|
2016-05-18 |
2023-07-01 |
Voyager Therapeutics Inc |
modulatory polynucleotides
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
JP2020511931A
(ja)
|
2016-06-16 |
2020-04-23 |
オスロ ウニヴェルスィテーツスィーケフース ハーエフOslo Universitetssykehus Hf |
改良された遺伝子編集
|
US11788083B2
(en)
|
2016-06-17 |
2023-10-17 |
The Broad Institute, Inc. |
Type VI CRISPR orthologs and systems
|
US20210222164A1
(en)
|
2016-06-29 |
2021-07-22 |
The Broad Institute, Inc. |
Crispr-cas systems having destabilization domain
|
CA3029860A1
(en)
|
2016-07-05 |
2018-01-11 |
The Johns Hopkins University |
Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter
|
AU2017295720B2
(en)
|
2016-07-13 |
2021-07-22 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
US11674158B2
(en)
|
2016-07-15 |
2023-06-13 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
AU2017306676B2
(en)
|
2016-08-03 |
2024-02-22 |
President And Fellows Of Harvard College |
Adenosine nucleobase editors and uses thereof
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
US20200283743A1
(en)
|
2016-08-17 |
2020-09-10 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
PL3504229T3
(pl)
|
2016-08-24 |
2022-04-19 |
Sangamo Therapeutics, Inc. |
Regulacja ekspresji genów przy użyciu nukleaz poddanych inżynierii
|
EP3504327B1
(en)
|
2016-08-24 |
2021-10-06 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
EP3831281A1
(en)
|
2016-08-30 |
2021-06-09 |
The Regents of The University of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
CN110214180A
(zh)
|
2016-10-14 |
2019-09-06 |
哈佛大学的校长及成员们 |
核碱基编辑器的aav递送
|
BR112019007210A2
(pt)
|
2016-10-20 |
2019-08-13 |
Sangamo Therapeutics Inc |
métodos e composições para o tratamento da doença de fabry
|
WO2018081775A1
(en)
|
2016-10-31 |
2018-05-03 |
Sangamo Therapeutics, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
MA49610A
(fr)
|
2016-12-08 |
2020-05-27 |
Univ Case Western Reserve |
Procédés et compositions pour améliorer la production de myéline fonctionnelle
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
KR20190130613A
(ko)
|
2017-03-23 |
2019-11-22 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
JP2020517638A
(ja)
|
2017-04-20 |
2020-06-18 |
エータイアー ファーマ, インコーポレイテッド |
肺の炎症を治療するための組成物および方法
|
CN110913866A
(zh)
|
2017-05-05 |
2020-03-24 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
US11752181B2
(en)
|
2017-05-05 |
2023-09-12 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
US20210278416A1
(en)
|
2017-05-09 |
2021-09-09 |
The Broad Institute, Inc. |
Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases
|
JP2020521807A
(ja)
|
2017-05-09 |
2020-07-27 |
ブイアイビー ブイゼットダブリュVib Vzw |
細菌感染を処置するための手段および方法
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
RU2769475C2
(ru)
|
2017-06-23 |
2022-04-01 |
Инскрипта, Инк. |
Направляемые нуклеиновыми кислотами нуклеазы
|
WO2019005884A1
(en)
|
2017-06-26 |
2019-01-03 |
The Broad Institute, Inc. |
CRISPR / CAS-ADENINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED NUCLEIC ACID EDITION
|
US11168322B2
(en)
|
2017-06-30 |
2021-11-09 |
Arbor Biotechnologies, Inc. |
CRISPR RNA targeting enzymes and systems and uses thereof
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
EP3662060A2
(en)
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
CA3073848A1
(en)
|
2017-09-21 |
2019-03-28 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
JP7502991B2
(ja)
|
2017-10-16 |
2024-06-19 |
ボイジャー セラピューティクス インコーポレイテッド |
筋萎縮性側索硬化症(als)の治療
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
EP3714054A1
(en)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
WO2019143675A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
EA202091708A1
(ru)
|
2018-01-17 |
2020-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы днк-пк
|
BR112020013626A2
(pt)
|
2018-01-17 |
2020-12-01 |
Vertex Pharmaceuticals Incorporated |
compostos de quinoxalinona, composições, métodos e kits para aumentar a eficiência de edição de genoma
|
WO2019160383A1
(ko)
|
2018-02-19 |
2019-08-22 |
고려대학교 산학협력단 |
열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
|
AU2019236210A1
(en)
|
2018-03-14 |
2020-09-10 |
Arbor Biotechnologies, Inc. |
Novel CRISPR DNA targeting enzymes and systems
|
WO2019178428A1
(en)
|
2018-03-14 |
2019-09-19 |
Arbor Biotechnologies, Inc. |
Novel crispr dna and rna targeting enzymes and systems
|
JP2021523739A
(ja)
|
2018-05-11 |
2021-09-09 |
ビーム セラピューティクス インク. |
プログラム可能な塩基エディターシステムを用いて単一ヌクレオチド多型を編集する方法
|
US20210198330A1
(en)
|
2018-05-23 |
2021-07-01 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
BR112020024863A2
(pt)
|
2018-06-05 |
2022-02-01 |
Lifeedit Inc |
Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
|
US20210301288A1
(en)
|
2018-07-16 |
2021-09-30 |
Arbor Biotechnologies, Inc. |
Novel crispr dna targeting enzymes and systems
|
EP3833761A1
(en)
|
2018-08-07 |
2021-06-16 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
TW202020157A
(zh)
|
2018-08-16 |
2020-06-01 |
美商艾爾妮蘭製藥公司 |
用於抑制lect2基因表現之組合物及方法
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
CA3111711A1
(en)
|
2018-09-18 |
2020-03-26 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
EP3867375A1
(en)
|
2018-10-15 |
2021-08-25 |
Fondazione Telethon |
Genome editing methods and constructs
|
BR112021007323A2
(pt)
|
2018-10-18 |
2021-07-27 |
Intellia Therapeutics, Inc. |
construtos de ácido nucleico e métodos para uso
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
US20220282275A1
(en)
|
2018-11-15 |
2022-09-08 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
US20220025367A1
(en)
|
2018-11-23 |
2022-01-27 |
Sanofi |
Novel rna compositions and methods for inhibiting angptl8
|
CA3124110A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
KR20210149686A
(ko)
|
2018-12-27 |
2021-12-09 |
라이프에디트 테라퓨틱스, 인크. |
유전자 편집에 유용한 폴리펩티드 및 사용 방법
|
CN113227404A
(zh)
|
2018-12-27 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
用于检测鲍氏不动杆菌的非复制型转导颗粒和基于转导颗粒的报告系统
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
WO2020191102A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Type vii crispr proteins and systems
|
EP3942040A1
(en)
|
2019-03-19 |
2022-01-26 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
WO2020210542A1
(en)
|
2019-04-09 |
2020-10-15 |
The Regents Of The University Of California |
Long-lasting analgesia via targeted in vivo epigenetic repression
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
EP3956349A1
(en)
|
2019-04-17 |
2022-02-23 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
EP3956474A1
(en)
|
2019-04-18 |
2022-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and prognosis of cancer
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
WO2020243485A1
(en)
|
2019-05-29 |
2020-12-03 |
Massachusetts Institute Of Technology |
Hiv-1 specific immunogen compositions and methods of use
|
WO2021016075A1
(en)
|
2019-07-19 |
2021-01-28 |
Flagship Pioneering Innovations Vi, Llc |
Recombinase compositions and methods of use
|
EP4010474A1
(en)
|
2019-08-08 |
2022-06-15 |
The Broad Institute, Inc. |
Base editors with diversified targeting scope
|
MX2022001849A
(es)
|
2019-08-12 |
2022-03-11 |
Lifeedit Therapeutics Inc |
Nucleasas guiadas por acido ribonucleico (arn) y sus fragmentos activos y variantes y metodos de uso.
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
US20220290156A1
(en)
|
2019-08-27 |
2022-09-15 |
Sanofi |
Compositions and methods for inhibiting pcsk9
|
EP4025694A1
(en)
|
2019-09-03 |
2022-07-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
WO2021050512A1
(en)
|
2019-09-09 |
2021-03-18 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
JP2022547570A
(ja)
|
2019-09-12 |
2022-11-14 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
操作済みのアデノ随伴ウイルスキャプシド
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021072328A1
(en)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
EP4051796A1
(en)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
KR20220115946A
(ko)
|
2019-11-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
|
US20230086199A1
(en)
|
2019-11-26 |
2023-03-23 |
The Broad Institute, Inc. |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
CN115190912A
(zh)
|
2019-12-30 |
2022-10-14 |
生命编辑制药股份有限公司 |
Rna指导核酸酶及其活性片段与变体以及使用方法
|
WO2021136752A1
(en)
|
2019-12-31 |
2021-07-08 |
F. Hoffmann-La Roche Ag |
Quantitative pcr screening of inducible prophage from bacterial isolates
|
WO2021155065A1
(en)
|
2020-01-28 |
2021-08-05 |
The Broad Institute, Inc. |
Base editors, compositions, and methods for modifying the mitochondrial genome
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
EP4100519A2
(en)
|
2020-02-05 |
2022-12-14 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
US20230108687A1
(en)
|
2020-02-05 |
2023-04-06 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Preparations and methods for silencing vegf-a expression
|
EP4127171A2
(en)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
BR112022020145A2
(pt)
|
2020-04-06 |
2023-01-03 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciamento da expressão de myoc
|
EP4133079A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
TW202208626A
(zh)
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna引導核酸酶及其活性片段與變體,以及使用方法
|
WO2021222318A1
(en)
|
2020-04-28 |
2021-11-04 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
EP4146812A1
(en)
|
2020-05-06 |
2023-03-15 |
Cellectis S.A. |
Methods for targeted insertion of exogenous sequences in cellular genomes
|
CA3177621A1
(en)
|
2020-05-06 |
2021-11-11 |
Alexandre Juillerat |
Methods to genetically modify cells for delivery of therapeutic proteins
|
MX2022014008A
(es)
|
2020-05-08 |
2023-02-09 |
Broad Inst Inc |
Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
|
CA3173882A1
(en)
|
2020-05-11 |
2021-11-18 |
Alexandra Briner CRAWLEY |
Rna-guided nucleic acid binding proteins and active fragments and variants thereof and methods of use
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
CA3173949A1
(en)
|
2020-07-15 |
2022-01-20 |
LifeEDIT Therapeutics, Inc. |
Uracil stabilizing proteins and active fragments and variants thereof and methods of use
|
US20230304047A1
(en)
|
2020-08-11 |
2023-09-28 |
University Of Oslo |
Improved gene editing
|
EP4204545A2
(en)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T cells with improved functionality
|
JP2023541400A
(ja)
|
2020-09-11 |
2023-10-02 |
ライフエディット セラピューティクス,インコーポレイティド |
Dna修飾酵素並びにその活性断片及びバリアント並びにその使用方法
|
WO2022079082A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffmann-La Roche Ag |
Nucleic acid constructs for simultaneous gene activation
|
CN116406425A
(zh)
|
2020-10-15 |
2023-07-07 |
豪夫迈·罗氏有限公司 |
用于va rna转录的核酸构建体
|
CN116887842A
(zh)
|
2020-10-16 |
2023-10-13 |
赛诺菲 |
用于抑制angptl3的新型rna组合物和方法
|
WO2022079221A1
(en)
|
2020-10-16 |
2022-04-21 |
Sanofi |
Rna compositions and methods for inhibiting lipoprotein(a)
|
AU2021365822A1
(en)
|
2020-10-21 |
2023-06-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
TW202237150A
(zh)
|
2020-12-01 |
2022-10-01 |
美商艾拉倫製藥股份有限公司 |
用於抑制hao1(羥基酸氧化酶1(乙醇酸氧化酶))基因表現的方法及組成物
|
TW202300649A
(zh)
|
2021-03-22 |
2023-01-01 |
美商生命編輯治療學公司 |
Dna修飾酶及活性片段及其變體及使用方法
|
AU2022245243A1
(en)
|
2021-03-23 |
2023-09-28 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
KR20240007651A
(ko)
|
2021-04-16 |
2024-01-16 |
빔 테라퓨틱스, 인크. |
간세포의 유전적 변형
|
CA3218475A1
(en)
|
2021-05-21 |
2022-11-24 |
Shipra DAS |
Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors
|
EP4349979A1
(en)
|
2021-05-27 |
2024-04-10 |
Institute Of Zoology, Chinese Academy Of Sciences |
Engineered cas12i nuclease, effector protein and use thereof
|
WO2022261509A1
(en)
|
2021-06-11 |
2022-12-15 |
The Broad Institute, Inc. |
Improved cytosine to guanine base editors
|
CA3173953A1
(en)
|
2021-06-11 |
2023-12-10 |
Tyson D. BOWEN |
Rna polymerase iii promoters and methods of use
|
KR20240026203A
(ko)
|
2021-06-30 |
2024-02-27 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
|
CA3225121A1
(en)
|
2021-07-20 |
2023-01-26 |
Benjamin DEVERMAN |
Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
CN114015674A
(zh)
|
2021-11-02 |
2022-02-08 |
辉二(上海)生物科技有限公司 |
新型CRISPR-Cas12i系统
|
CA3240917A1
(en)
|
2021-12-17 |
2023-06-22 |
Bernd ZETSCHE |
Crispr enzymes, methzods, systems and uses thereof
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023139557A1
(en)
|
2022-01-24 |
2023-07-27 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2023196772A1
(en)
|
2022-04-04 |
2023-10-12 |
Beam Therapeutics Inc. |
Novel rna base editing compositions, systems, methods and uses thereof
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023196802A1
(en)
|
2022-04-04 |
2023-10-12 |
The Broad Institute, Inc. |
Cas9 variants having non-canonical pam specificities and uses thereof
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220693A1
(en)
|
2022-05-12 |
2023-11-16 |
SunVax mRNA Therapeutics Inc. |
Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
|
WO2023225564A1
(en)
|
2022-05-18 |
2023-11-23 |
The Broad Institute, Inc. |
Engineered viral capsids with increased stability and methods of use thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023227438A1
(en)
|
2022-05-23 |
2023-11-30 |
F. Hoffmann-La Roche Ag |
Raman-based method for the differentiation of aav particle serotype and aav particle loading status
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
WO2023232922A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2023240137A1
(en)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
|
WO2024003334A1
(en)
|
2022-06-30 |
2024-01-04 |
Cellectis S.A. |
Enhancing safety of t-cell-mediated immunotherapy
|
WO2024013239A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
WO2024016003A2
(en)
|
2022-07-14 |
2024-01-18 |
The Broad Institute, Inc. |
Aav capsids that enable cns-wide gene delivery through interactions with the transferrin receptor
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024042489A1
(en)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
WO2024056561A1
(en)
|
2022-09-12 |
2024-03-21 |
F. Hoffmann-La Roche Ag |
Method for separating full and empty aav particles
|
WO2024059791A1
(en)
|
2022-09-16 |
2024-03-21 |
Beam Therapeutics Inc. |
Large serine recombinases, systems and uses thereof
|
WO2024094775A1
(en)
|
2022-11-03 |
2024-05-10 |
Cellectis S.A. |
Enhancing efficacy and safety of t-cell-mediated immunotherapy
|
WO2024095245A2
(en)
|
2022-11-04 |
2024-05-10 |
LifeEDIT Therapeutics, Inc. |
Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
|
WO2024098061A2
(en)
|
2022-11-04 |
2024-05-10 |
Genkardia Inc. |
Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
|
WO2024108217A1
(en)
|
2022-11-18 |
2024-05-23 |
Genkardia Inc. |
Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction
|
WO2024127369A1
(en)
|
2022-12-16 |
2024-06-20 |
LifeEDIT Therapeutics, Inc. |
Guide rnas that target foxp3 gene and methods of use
|
WO2024127370A1
(en)
|
2022-12-16 |
2024-06-20 |
LifeEDIT Therapeutics, Inc. |
Guide rnas that target trac gene and methods of use
|